ICOSAVAX, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-06-10: Study NCT06481579; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2023-05-15: Study NCT05903183; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2022-09-21: Study NCT05664334; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-06-10 | NCT06481579 A Study of IVX-A12 in Adults Participants | Lead sponsor | Phase 2 | Completed Results posted | Healthy Participants | 143 | 2024-12-19 |
| 2023-05-15 | NCT05903183 A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age | Lead sponsor | Phase 2 | Completed Results posted | Healthy | 264 | 2024-10-25 |
| 2022-09-21 | NCT05664334 Safety and Immunogenicity of IVX-A12 in Healthy Older Adults | Lead sponsor | Phase 1 | Completed | Healthy | 140 | 2024-01-24 |